Conference Call with Mankind Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Mankind Pharma announced Q2FY26 results Revenue from Operations at Rs 3,697 crore, up by 20.8% YoY. Domestic revenue at Rs 3,184 crore, up 14.5%, Exports at Rs 513 crore, up 82.6% YoY. Reported EBITDA margin of 25.0% and PAT margin of 14.1%. Diluted EPS of Rs 12.4 down by 24.2% YoY (FV Re.1). Rajeev Juneja, Vice Chairman & Managing Director, said: “Mankind’s revenue increased by 20.8% supported by outperformance in Chronic and BSV consolidation, partially impacted by GST disruption. While chronic continued an outperformance led by 1.3x and 1.2x in Cardiac and Antidiabetes respectively, OTC was impacted due to heavy rains along with GST 2.0 and we expect growth recovery in H2. BSV growth initiatives progressing well - with double digit sequential growth led by mandate brands. We remain confident of delivering sustainable long-term growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio.” Result PDF